| Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study D Abrahami, A Douros, H Yin, OHY Yu, C Renoux, A Bitton, L Azoulay bmj 360, 2018 | 120 | 2018 |
| Proton pump inhibitors and risk of gastric cancer: population-based cohort study D Abrahami, EG McDonald, ME Schnitzer, AN Barkun, S Suissa, ... Gut 71 (1), 16-24, 2022 | 82 | 2022 |
| Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study D Abrahami, A Douros, H Yin, HY Oriana, JL Faillie, F Montastruc, ... bmj 363, 2018 | 51 | 2018 |
| Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study D Abrahami, EG McDonald, M Schnitzer, L Azoulay BMJ open 10 (12), e041529, 2020 | 43 | 2020 |
| Proton pump inhibitors and risk of colorectal cancer D Abrahami, EG McDonald, ME Schnitzer, AN Barkun, S Suissa, ... Gut 71 (1), 111-118, 2022 | 30 | 2022 |
| Sodium–glucose cotransporter 2 inhibitors and the risk of fractures among patients with type 2 diabetes D Abrahami, A Douros, H Yin, OHY Yu, L Azoulay Diabetes Care 42 (9), e150-e152, 2019 | 30 | 2019 |
| Use of real‐world data to emulate a clinical trial and support regulatory decision making: assessing the impact of temporality, comparator choice, and method of adjustment D Abrahami, R Pradhan, H Yin, P Honig, E Baumfeld Andre, L Azoulay Clinical Pharmacology & Therapeutics 109 (2), 452-461, 2021 | 18 | 2021 |
| Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes D Abrahami, H Yin, HY Oriana, MN Pollak, L Azoulay Epidemiology 29 (2), 246-253, 2018 | 18 | 2018 |
| Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes A Douros, D Abrahami, H Yin, OHY Yu, C Renoux, M Hudson, L Azoulay Epidemiology 29 (6), 904-912, 2018 | 16 | 2018 |
| Sodium–glucose cotransporter 2 inhibitors and the short-term risk of bladder cancer: an international multisite cohort study D Abrahami, H Tesfaye, H Yin, S Vine, B Hicks, OHY Yu, L Campeau, ... Diabetes Care 45 (12), 2907-2917, 2022 | 11 | 2022 |
| Trends in prescribing patterns of proton pump inhibitors surrounding new guidelines D Abrahami, EG McDonald, M Schnitzer, L Azoulay Annals of Epidemiology 55, 24-26, 2021 | 10 | 2021 |
| Statins and lower mortality in rheumatic diseases: An effect of immortal time bias? D Abrahami, M Hudson, S Suissa Seminars in Arthritis and Rheumatism 51 (1), 211-218, 2021 | 10 | 2021 |
| Contemporary trends in the utilization of second‐line pharmacological therapies for type 2 diabetes in the United States and the United Kingdom D Abrahami, E D'Andrea, H Yin, SC Kim, JM Paik, D Wexler, L Azoulay, ... Diabetes, Obesity and Metabolism 25 (10), 2980-2988, 2023 | 7 | 2023 |
| Proton pump inhibitors and the risk of inflammatory bowel disease: population-based cohort study D Abrahami, R Pradhan, H Yin, R Yanofsky, EG McDonald, A Bitton, ... Gut 72 (7), 1288-1295, 2023 | 7 | 2023 |
| The association between oral anticoagulants and cancer incidence among individuals with nonvalvular atrial fibrillation D Abrahami, C Renoux, H Yin, JP Fournier, L Azoulay Thrombosis and Haemostasis 120 (10), 1384-1394, 2020 | 7 | 2020 |
| Defining clinically relevant target populations using real‐world data to guide the design of representative antidiabetic drug trials R Pradhan, D Abrahami, H Yin, OHY Yu, V Sahasrabudhe, ... Clinical Pharmacology & Therapeutics 109 (5), 1219-1223, 2021 | 6 | 2021 |
| Continuous glucose monitoring in adults with diabetes in clinical practice: increased access and education needed D Abrahami, S Hernández-Díaz, MN Munshi, E Patorno Journal of General Internal Medicine 38 (8), 2011-2014, 2023 | 1 | 2023 |
| Trends and prescription patterns of medications for secondary stroke prevention in Denmark, 2013-2018 N Skajaa, D Abrahami, K Adelborg, HT Sorensen, J Lauffenburger, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 31, 29-30, 2022 | 1 | 2022 |
| Response by Abrahami et al to letter regarding article ‘Proton pump inhibitors and risk of colorectal cancer’ D Abrahami, L Azoulay Gut 71 (8), 1690-1691, 2022 | 1 | 2022 |
| 1086-P: Cardiovascular effectiveness of SGLT2 inhibitors: head-to-head comparisons D Abrahami, E D’ANDREA, JM Paik, DJ Wexler, BM Everett, SC Kim, ... Diabetes 71 (Supplement_1), 2022 | 1 | 2022 |
